We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

DHMRI and Metabolon Announce Strategic Partnership

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

The David H. Murdock Research Institute (DHMRI) and Metabolon, Inc. have announced that they have entered into a strategic agreement to align metabolomics research services.

Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc.

The agreement complements DHMRI’s mass spectrometry and NMR-based metabolomics services through access to Metabolon’s industry-leading high-throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.

“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, Senior Vice President of Sales & Marketing for Metabolon.

DHMRI is an established not-for-profit research institute that provides flexible, client-focused research services to academia, government and industry collaborators.

This agreement, consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics.

Metabolon’s global metabolomic approach can pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.

“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily realized by researchers, companies and consumers,” said Steve Lommel, Ph.D., Interim President, David H. Murdock Research Institute.